Which antidepressant class is typically associated with the risk of weight gain?

The class of antidepressants typically associated with the risk of weight gain is the tricyclic antidepressants (TCAs). TCAs are known to influence various neurotransmitters in the brain, particularly serotonin and norepinephrine. This mechanism, while effective for alleviating depressive symptoms, can also lead to side effects, including weight gain.

The anticholinergic properties of many TCAs can cause increased appetite, as well as metabolic changes that may contribute to weight gain. This can make TCAs less desirable for some patients, particularly those who are concerned about weight management during treatment.

In contrast, other classes of antidepressants have variable effects on weight. Selective Serotonin Reuptake Inhibitors (SSRIs) may be neutral or sometimes associated with weight loss initially, while Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs) are often associated with weight loss. Monoamine Oxidase Inhibitors (MAOIs) do not have a consistent relationship with weight gain when compared to TCAs, making the latter the most notable in terms of this side effect.